{"brief_title": "An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes", "brief_summary": "The purpose of this study is to determine if an investigational drug is safe and efficacious for poorly controlled type 2 diabetes mellitus.", "condition": ["Diabetes Mellitus, Non-Insulin-Dependent"], "intervention_type": ["Drug"], "intervention_name": ["naveglitazar"], "criteria": "Inclusion Criteria: - Diagnosis of Type 2 Diabetes for at least 3 months. - Diabetes managed with diet and exercise alone or with either metformin or sulfonylurea alone as an adjunct to diet and exercise. - Diabetes therapy must be unchanged for at least 3 months prior to screening. - Females must be of non-childbearing potential (surgically sterilized or at least 1 year post-menopausal, as defined by cessation of menses). Female patients who are not surgically sterilized and who are less than or equal to 45 years should have their post-menopausal status confirmed by FSH greater that 30ng/mL at screening. Exclusion Criteria: - Current use of insulin or any antidiabetic agent other than a sulfonylurea agent or metformin. - Current use of metformin or a sulfonylurea agent in combination. - History of liver disease. - History of unstable angina (as defined by the Braunwald system), myocardial infarction, or a coronary revascularization procedure within the past 6 months. - Currently suspected carcinoma or history of carcinoma in the last 5 years, with the exception of excised superficial lesions such as basal cell carcinoma and squamous cell carcinoma of the skin.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "70 Years", "healthy_volunteers": "No", "keyword": "Type 2 diabetes", "mesh_term": ["Diabetes Mellitus", "Diabetes Mellitus, Type 2"], "id": "NCT00065312"}